Pembrolizumab Medicine 03 June 2025 Extended indication Pembrolizumab in combination with gemcitabine and cisplatin followed by surgery and postoperative pembrolizumab for neoadjuvant treatment of non-metastatic muscle invasive Bladder cancer in adults and elderly who are eligible for radical cystectomy and pelvic lymph node dissection. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Pembrolizumab Domain Oncology Reason of inclusion Indication extension IND Main indication Bladder cancer Extended indication Pembrolizumab in combination with gemcitabine and cisplatin followed by surgery and postoperative pembrolizumab for neoadjuvant treatment of non-metastatic muscle invasive Bladder cancer in adults and elderly who are eligible for radical cystectomy and pelvic lymph node dissection. Current proprietary name Already available biosimilars / generics Proprietary name Keytruda Manufacturer MSD Portfolio holder Mechanism of action PD-1 / PD-L1 inhibitor Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date 2026 Expected Registration January 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Out of the sluice Additional remarks Voor alle indicaties van pembrolizumab geldt een financieel arrangement tot 1 januari 2027. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times every 3 weeks Dosage per administration 200mg References NCT03924856 (KEYNOTE-866) Additional remarks Expected patient volume per year Patient volume < 1,600 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References IKNL; expertopinie Additional remarks Volgens IKNL worden in Nederland jaarlijks ongeveer 5.400 patiënten primair gediagnosticeerd met niet-spier-invasieve blaaskanker (NMIBC) — dit betreft Ta-, T1- en CIS-laesies. 1.600 patiënten krijgen primair de diagnose spier-invasieve blaaskanker (MIBC). Expected cost per patient per year Cost References Additional remarks Voor alle indicaties van pembrolizumab geldt een financieel arrangement. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks